Session Name: Kidney: Acute Cellular Rejection
Session Date & Time: None. Available on demand.
*Purpose: Subclinical rejection (SCR) is associated with chronic allograft nephropathy, which is the most common cause of allograft failure in kidney transplantation (KT). Therefore, early detection and treatment of subclinical rejection through protocol biopsy can reduces the incidence of chronic allograft nephropathy and the improvement of graft survival. This study aims to evaluate the effective early detection role of routine protocol biopsy by comparing the pathologic outcome.
*Methods: We retrospectively analyzed 914 kidney transplantation recipients in our center between August 2012 and December 2018. Of these, pediatric cases, re-transplantations and multi-organ transplantation, cyclosporine and azathioprine users, patients who were not underwent protocol biopsy, and diagnosed rejection but not treated patients were excluded. Finally, a total of 624 adult patients who were underwent protocol biopsy at post KT 2 weeks and 1 year were analyzed.
*Results: After propensity score matching, patients were divided into two groups, 2-week protocol biopsy proven normal group (n=256) and rejection group (n=96). Before propensity matching, normal group was significant higher recipient age and ABO incompatible KT, rejection group was higher HLA II mismatch and proportion of deceased donor KT, the difference was corrected through matching. Rejection group showed no significant difference from normal group in the tendency of graft function (eGFR), and Kaplan-Meire curve also shown that in graft survival. In the pathologic outcomes between two groups and two periods, the pathological differences between two groups showed a decrease between two periods.
*Conclusions: Subclinical rejection treatment through protocol biopsy can contribute to maintenance of graft function and improvement of pathologic change.
To cite this abstract in AMA style:Lee O, Lee K, Park J, Lee J, Kwon G, Kim K. Impact of Treatment of Subclinical Rejection at 2 Weeks After Kidney Transplantation, Compared by 1 Year Histologic Outcomes [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-treatment-of-subclinical-rejection-at-2-weeks-after-kidney-transplantation-compared-by-1-year-histologic-outcomes/. Accessed June 13, 2021.
« Back to 2021 American Transplant Congress